Evidence map›Paper›PMID 41548030›Full record

SynthesisBritish journal of cancer2026

Effects of preoperative recombinant Interleukin 2-based immunomodulation on outcome after gastrointestinal cancer surgery: a systematic review and meta-analysis.

A Horcicka, N Bewersdorf, E Kalkum, S Zimmermann, L Grüßer, S Dehne, M A Weigand, R Klotz, J Larmann

Abstract readSystematic ReviewMeta-Analysis
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in British journal of cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

A Horcicka *Department of Anaesthesiology, Medical Faculty Heidelberg, Heidelberg University, Heidelberg, Germany.
N Bewersdorf *Department of Anaesthesiology, Medical Faculty Heidelberg, Heidelberg University, Heidelberg, Germany.
E KalkumThe Study Centre of the German Surgical Society, Heidelberg University Hospital, Heidelberg, Germany.
S ZimmermannMedical Faculty Heidelberg, Institute for Medical Biometry, Heidelberg University, Heidelberg, Germany.
L GrüßerDepartment of Anaesthesiology, Medical Faculty, RWTH Aachen University, Aachen, Germany.
S DehneDepartment of Anaesthesiology, Medical Faculty Heidelberg, Heidelberg University, Heidelberg, Germany.
M A WeigandDepartment of Anaesthesiology, Medical Faculty Heidelberg, Heidelberg University, Heidelberg, Germany.
R KlotzDepartment of General, Visceral and Transplant Surgery, Medical Faculty Heidelberg, Heidelberg University, Heidelberg, Germany.
J LarmannDepartment of Anaesthesiology, Medical Faculty Heidelberg, Heidelberg University, Heidelberg, Germany. jlarmann@ukaachen.de.ORCID http://orcid.org/0000-0003-3365-4572

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundPatients undergoing gastrointestinal cancer surgery are often immunocompromised and susceptible to infectious complications. Recombinant Interleukin 2 activates effector immune cells and stimulates the expansion of regulatory T-cells, making it a promising intervention for prevention of inflammatory complications.

objectiveOur objective was to investigate effects of different preoperative rIL2 dosages on postoperative outcome parameters.

methodsWe conducted a systematic literature review and meta-analysis and included RCTs that recruited adult patients undergoing gastrointestinal cancer surgery who received preoperative subcutaneous rIL2. We performed a systematic search of MEDLINE (via PubMed), Web of Science and the Cochrane Central Register of Controlled Trials (CENTRAL) from 1989 up to April 18th, 2024.

resultsOut of 2324 screened studies, we included 13 RCTs with a total of 504 patients. Lymphocyte counts [cells/mm

conclusionPreoperative rIL2-based immunomodulation prevents postoperative immunosuppression while the occurrence of severe side effects does not seem to be relevant.

Indexed as

Gastrointestinal NeoplasmsImmunomodulationInterleukin-2HumansPreoperative CareRecombinant ProteinsInterleukin-2Recombinant Proteins

Identifiers

PMID41548030
PMCPMC12996586

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.